The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Maintaining Patient Safety and Data Integrity of NASH Clinical Trials During the SARS-CoV-2 Pandemic
Hepatology. 2020 Aug 14;10.1002/hep.31522. doi: 10.1002/hep.31522. Online ahead of print.
Naim Alkhouri1, Anita Kohli1, Rohit Loomba2, Stephen A Harrison3
Author information
1Arizona Liver Health, Chandler, AZ, United States.
2Division of Gastroenterology, Department of Medicine and Division of Epidemiology, Department of Family and Preventive, University of California at San Diego, NAFLD Research Center, University of California at San Diego, La Jolla, CA, United States.
3Pinnacle Clinical Research, San Antonio, TX, United States, Chandler.
Abstract
Coronavirus disease 2019 (COVID-19), the illness caused by the SARS-CoV-2 virus, has spread rapidly throughout the world overwhelming healthcare systems. Fever and cough are the dominant symptoms with 15% of patients developing severe illness especially in the elderly and those with concurrent illnesses. Quarantine, shelter in place, and social distancing strategies have been instituted, restricting people from going out for all but essential services. The prevalence of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), have steadily increased and now affect approximately 25% of the global population.